Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia.

Next Previous
X
Search
Trial Profile

First-in-Patient Study to Assess the Safety and Tolerability and to Explore the Potential Therapeutic Efficacy of a Novel Glutamate Modulator as Monotherapy and as Add-On Therapy in Patients With Schizophrenia.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADX 71149 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 05 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 28 May 2013 Data has been presented at the 2013 Annual Meeting of the American Psychiatry Association, according to an Addex Therapeutics media release.
    • 05 Nov 2012 Results from the double-blind component o the trial (part B) have been reported in an Addex Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top